Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -20.73% is 78% above its 5-year average of -93.79%, near the high end of its 5-year range (-162.60%–10.16%).
23.88% above its 12-month average of -27.23%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -55.61%.
NET PROFIT MARGIN
-20.73%
NET PROFIT MARGIN AVG TTM
-27.23%
NET PROFIT MARGIN AVG 3Y
-71.97%
NET PROFIT MARGIN AVG 5Y
-93.79%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+23.88%
CURRENT VS 3Y AVG
+71.20%
CURRENT VS 5Y AVG
+77.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 563 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Adaptive Biotechnologies Corporation
Market Cap
$4.56B
Net Profit Margin
-20.73%
TTM Avg
-27.23%
3Y Avg
-71.97%
5Y Avg
-93.79%
Market Cap
$4.69B
Net Profit Margin
3.19%
TTM Avg
-1.95%
3Y Avg
-11.66%
5Y Avg
-17.12%
Market Cap
$4.42B
Net Profit Margin
26.65%
TTM Avg
8.56%
3Y Avg
0.11%
5Y Avg
0.58%
Market Cap
$4.41B
Net Profit Margin
-55.82%
TTM Avg
-71.50%
3Y Avg
-84.24%
5Y Avg
-84.24%
Market Cap
$4.66B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.71B
Net Profit Margin
-1570.85%
TTM Avg
-4668.05%
3Y Avg
-2830.27%
5Y Avg
-2034.87%
Market Cap
$4.29B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.82B
Net Profit Margin
-139.18%
TTM Avg
-15.29%
3Y Avg
-73.58%
5Y Avg
-122.19%
Market Cap
$4.91B
Net Profit Margin
8.43%
TTM Avg
-12.40%
3Y Avg
-46.69%
5Y Avg
-46.69%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation (ADPT) | $4.56B | -20.73% | -27.23% | -71.97% | -93.79% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 3.19% | -1.95% | -11.66% | -17.12% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.42B | 26.65% | 8.56% | 0.11% | 0.58% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.41B | -55.82% | -71.50% | -84.24% | -84.24% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.66B | 0.00% | 0.00% | 0.00% | 0.00% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.71B | -1570.85% | -4668.05% | -2830.27% | -2034.87% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.29B | 0.00% | 0.00% | 0.00% | 0.00% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.82B | -139.18% | -15.29% | -73.58% | -122.19% |
| BillionToOne, Inc. (BLLN)vs › | $4.91B | 8.43% | -12.40% | -46.69% | -46.69% |
| LivaNova PLC (LIVN)vs › | $4.18B | 12.82% | -6.21% | -4.84% | -11.63% |
Operating Margin
-20.6%
Net Profit Margin
-20.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -55.61% |
| 2026-03-31 | -28.27% |
| 2025-12-31 | -18.94% |
| 2025-09-30 | 10.16% |
| 2025-06-30 | -43.50% |
| 2025-03-31 | -56.92% |
| 2024-12-31 | -70.99% |
| 2024-09-30 | -69.07% |
| 2024-06-30 | -107.02% |
| 2024-03-31 | -113.45% |
| 2023-12-31 | -151.67% |
| 2023-09-30 | -132.65% |
| 2023-06-30 | -97.72% |
| 2023-03-31 | -153.26% |
| 2022-12-31 | -72.70% |
| 2022-09-30 | -94.67% |
| 2022-06-30 | -119.21% |
| 2022-03-31 | -162.60% |
| 2021-12-31 | -161.71% |
| 2021-09-30 | -141.64% |
| 2021-06-30 | -128.04% |
| 2021-03-31 | -105.72% |
| 2020-12-31 | -147.66% |
| 2020-09-30 | -139.62% |
| 2020-06-30 | -159.78% |
| 2020-03-31 | -150.18% |
| 2019-12-31 | -85.14% |
| 2019-09-30 | -53.53% |
| 2019-06-30 | -70.73% |
| 2019-03-31 | -145.16% |
| 2018-12-31 | -77.19% |
| 2018-09-30 | -48.24% |
| 2018-06-30 | -108.00% |
| 2018-03-31 | -127.55% |
